STAT June 3, 2024
Matthew Herper

CHICAGO — Delfi Diagnostics, a company seeking to develop liquid biopsy tests to help screen for lung cancer, published a scientific paper on Monday describing key aspects of the test and unveiled the design of a key clinical trial.

Delfi also announced that the Merck Global Health Innovation Fund, the VC arm of the drug giant, has made an investment of an undisclosed amount in the company.

Unlike Grail, a unit of Illumina,...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: Clinical Trials, Medical Devices, Trends
AI-Enabled Hand Sensor May Reduce Nocturnal Scratching Due to Mild Eczema
AI Hand Sensor Reduces Night Scratching in Atopic Dermatitis
The capital required for AI-enabled medical devices
Miist Therapeutics Raises $7M to Develop Inhaled Medicines with Physics-Based Approach
70% of People with Diabetes Feel Stigma: Abbott Survey Reveals Challenges

Share This Article